Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $300K | $363K | $1.11M | $250K | — | $512K | — | $210K | $210K | — |
| Revenue growth | — | 20.8% | 206.9% | -77.5% | — | — | — | — | 0.0% | — |
| Operating income | -$4.51M | -$6.08M | -$14.3M | -$11.9M | -$9.98M | -$13.1M | -$13.9M | -$11.0M | -$13.8M | -$11.7M |
| Operating margin | -1503.0% | -1676.0% | -1284.4% | -4756.0% | — | -2565.6% | — | -5243.3% | -6586.2% | — |
| Net income | -$5.02M | -$5.01M | -$14.0M | -$11.6M | -$10.0M | -$13.0M | -$13.6M | -$9.81M | -$12.6M | -$10.9M |
| Net margin | -1672.1% | -1381.8% | -1258.1% | -4658.8% | — | -2530.1% | — | -4671.9% | -5978.1% | — |
| EPS (diluted) | -$0.57 | -$0.58 | -$0.79 | -$0.59 | -$0.45 | -$0.45 | $0.45 | -$0.32 | -$0.39 | -$0.34 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.38M | -$3.80M | -$4.27M | -$4.74M | -$6.18M | -$4.94M | -$6.49M | -$6.21M | -$7.33M | -$7.17M |
| Capital expenditures | $147K | $30.2K | $38.4K | $175K | $15.8K | — | — | — | — | — |
| Free cash flow | -$3.53M | -$3.83M | -$4.31M | -$4.92M | -$6.19M | — | — | — | — | — |
| Share buybacks | — | — | — | — | — | — | — | — | $6.00K | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.49M | $3.34M | $3.06M | $3.49M | $6.42M | $29.1M | $12.4M | $915K | $1.27M | $1.24M |
| Total assets | $5.63M | $8.81M | $6.45M | $6.29M | $9.45M | $36.3M | $30.4M | $25.5M | $21.6M | $16.1M |
| Total liabilities | $4.64M | $889K | — | — | $1.19M | $1.49M | $2.21M | $2.15M | $2.70M | $2.13M |
| Shareholders' equity | $987K | $7.92M | $5.43M | $5.24M | $8.76M | $35.4M | $29.0M | $24.3M | $20.0M | $15.2M |
| Retained earnings | -$151M | -$156M | -$170M | -$182M | -$192M | -$205M | -$218M | -$228M | -$241M | -$252M |
| Shares (wtd avg diluted) | 8.75M | 16.6M | 18.9M | 20.3M | 24.2M | 28.6M | 30.4B | 31.0B | 31.9B | 32.5B |
Every figure is extracted from Anixa Biosciences Inc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.